摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-氯-4-羟基-5硝基吡啶 | 31872-64-7

中文名称
3-氯-4-羟基-5硝基吡啶
中文别名
3-氯-4-羟基-5-硝基吡啶
英文名称
3-chloro-5-nitropyridin-4-ol
英文别名
3-Nitro-4-hydroxy-5-chlor-pyridin
3-氯-4-羟基-5硝基吡啶化学式
CAS
31872-64-7
化学式
C5H3ClN2O3
mdl
MFCD11044290
分子量
174.543
InChiKey
VEOKYVSPRSTYHS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    263℃
  • 沸点:
    339.3±37.0 °C(Predicted)
  • 密度:
    1.664±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    74.9
  • 氢给体数:
    1
  • 氢受体数:
    4

安全信息

  • 危险品标志:
    Xn
  • 危险类别码:
    R22
  • WGK Germany:
    3
  • 海关编码:
    2933399090
  • 危险性防范说明:
    P280,P305+P351+P338
  • 危险性描述:
    H302

SDS

SDS:96c4bdc6c87f75938da4ed6e18d46c33
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 3-Chloro-5-nitropyridin-4-ol
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 3-Chloro-5-nitropyridin-4-ol
CAS number: 31872-64-7

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H3ClN2O3
Molecular weight: 174.5

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
    4-羟基-3-硝基吡啶 4-hydroxy-3-nitropyridine 5435-54-1 C5H4N2O3 140.098
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    3-氯-5-硝基吡啶-4-胺 3-Nitro-4-amino-5-chlor-pyridin 89284-28-6 C5H4ClN3O2 173.559
    3,4-二氯-5-硝基吡啶 3,4-dichloro-5-nitropyridine 56809-84-8 C5H2Cl2N2O2 192.989

反应信息

  • 作为反应物:
    描述:
    3-氯-4-羟基-5硝基吡啶盐酸 、 tin(ll) chloride 、 三氯氧磷 作用下, 以 乙醚N,N-二甲基甲酰胺 为溶剂, 反应 2.5h, 生成 3-氨基-4,5-二氯吡啶
    参考文献:
    名称:
    7‘-Substituted Benzothiazolothio- and Pyridinothiazolothio-Purines as Potent Heat Shock Protein 90 Inhibitors
    摘要:
    We report on the discovery of benzo- and pyridino-thiazolothiopurines as potent heat shock protein 90 inhibitors. The benzothiazole moiety is exceptionally sensitive to substitutions on the aromatic ring with a 7'-substituent essential for activity. Some of these compounds exhibit low nanomolar inhibition activity in a Her-2 degradation assay (28-150 nM), good aqueous solubility, and oral bioavailability profiles in mice. In vivo efficacy experiments demonstrate that compounds of this class inhibit tumor growth in an N87 human colon cancer xenograft model via oral administration as shown with compound 37 (8-(7-chlorobenzothiazol-2- ylsulfanyl)-9-(2-cyclopropylamino-ethyl)-9H-purin-6-ylamine).
    DOI:
    10.1021/jm051146h
  • 作为产物:
    描述:
    4-羟基-3-硝基吡啶溶剂黄146 作用下, 以 为溶剂, 反应 20.0h, 以97%的产率得到3-氯-4-羟基-5硝基吡啶
    参考文献:
    名称:
    [EN] 1,3 -DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH HETEROCYCLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS
    [FR] DÉRIVÉS 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE SUBSTITUÉS PAR DES HÉTÉROCYCLES COMME AGENTS ANTIVIRAUX ANTI-VIRUS RESPIRATOIRE SYNCYTIAL
    摘要:
    本发明涉及具有具有式(I)的杂环取代物的新颖的4-取代的1,3-二氢-2H-苯并咪唑-2-酮衍生物的构象异构体和立体异构体,以及其药学上可接受的加合物和溶剂合物,其中R4、R5、Z和Het在权利要求中定义。根据本发明的化合物可用作呼吸道合胞病毒(RSV)复制的抑制剂。本发明还涉及制备这种新颖化合物、包含这些化合物的组合物,以及用于治疗呼吸道合胞病毒感染的化合物。
    公开号:
    WO2013186335A1
点击查看最新优质反应信息

文献信息

  • [EN] N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS<br/>[FR] DÉRIVÉS DE N-(HÉTÉROARYL)-SULFONAMIDE UTILES COMME INHIBITEURS DE S100
    申请人:ACTIVE BIOTECH AB
    公开号:WO2014184234A1
    公开(公告)日:2014-11-20
    A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.
    化合物的化学式(I),或其药学上可接受的盐以及包含该化合物的药物组合物。该化合物是S100A9与相互作用伙伴(如RAGE、TLR4和EMMPRIN)之间相互作用的抑制剂,因此在治疗癌症、自身免疫性疾病、炎症性疾病和神经退行性疾病等疾病方面具有用处。
  • [EN] 1,3 -DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH HETEROCYCLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS<br/>[FR] DÉRIVÉS 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE SUBSTITUÉS PAR DES HÉTÉROCYCLES COMME AGENTS ANTIVIRAUX ANTI-VIRUS RESPIRATOIRE SYNCYTIAL
    申请人:JANSSEN R & D IRELAND
    公开号:WO2013186335A1
    公开(公告)日:2013-12-19
    The present invention is concerned with novel 4-substituted 1,3-dihydro-2H-benzimidazol-2-one derivatives substituted with heterocycles having formula (I) tautomers and stereoisomeric forms thereof, and the pharmaceutically acceptable addition salts, and the solvates thereof, wherein R4, R5, Z and Het have the meaning defined in the claims. The compounds according to the present invention are useful as inhibitors on the replication of the respiratory syncytial virus (RSV). The invention further concerns the preparation of such novel compounds, compositions comprising these compounds, and the compounds for use in the treatment of respiratory syncytial virus infection.
    本发明涉及具有具有式(I)的杂环取代物的新颖的4-取代的1,3-二氢-2H-苯并咪唑-2-酮衍生物的构象异构体和立体异构体,以及其药学上可接受的加合物和溶剂合物,其中R4、R5、Z和Het在权利要求中定义。根据本发明的化合物可用作呼吸道合胞病毒(RSV)复制的抑制剂。本发明还涉及制备这种新颖化合物、包含这些化合物的组合物,以及用于治疗呼吸道合胞病毒感染的化合物。
  • [EN] 4 - SUBSTITUTED 1, 3 - DIHYDRO - 2H - BENZIMIDAZOL - 2 - ONE DERIVATIVES SUBSTITUTED WITH BENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS<br/>[FR] DÉRIVÉS DE 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE SUBSTITUÉS EN POSITION 4 PAR DES BENZIMIDAZOLES UTILISÉS COMME AGENTS ANTIVIRAUX CONTRE LE VIRUS RESPIRATOIRE SYNCYTIAL
    申请人:JANSSEN R & D IRELAND
    公开号:WO2013186332A1
    公开(公告)日:2013-12-19
    The present invention is concerned with novel 4-substituted 1,3-dihydro-2H- benzimidazol-2-one derivatives substituted with benzimidazoles having formula (I), tautomers and stereoisomeric forms thereof, and the pharmaceutically acceptable addition salts, and the solvates thereof, wherein R4, R5, Z and Het have the meaning defined in the claims. The compounds according to the present invention are useful as inhibitors on the replication of the respiratory syncytial virus (RSV). The invention further concerns the preparation of such novel compounds, compositions comprising these compounds, and the compounds for use in the treatment of respiratory syncytial virus infection.
    本发明涉及具有式(I)的苯并咪唑基取代的新型4-取代的1,3-二氢-2H-苯并咪唑-2-酮衍生物,其异构体和立体异构体形式,以及其药学上可接受的加合物和溶剂合物,其中R4、R5、Z和Het在权利要求中定义了含义。根据本发明的化合物可用作对呼吸道合胞病毒(RSV)复制的抑制剂。本发明还涉及制备这种新型化合物,包含这些化合物的组合物,以及用于治疗呼吸道合胞病毒感染的化合物。
  • 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH HETEROCYCLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS
    申请人:Janssen R&D Ireland
    公开号:US20150158862A1
    公开(公告)日:2015-06-11
    The present invention is concerned with novel 4-substituted 1,3-dihydro-2H-benzimidazol-2-one derivatives substituted with heterocycles having formula (I) tautomers and stereoisomeric forms thereof, and the pharmaceutically acceptable addition salts, and the solvates thereof, wherein R 4 , R 5 , Z and Het have the meaning defined in the claims. The compounds according to the present invention are useful as inhibitors on the replication of the respiratory syncytial virus (RSV). The invention further concerns the preparation of such novel compounds, compositions comprising these compounds, and the compounds for use in the treatment of respiratory syncytial virus infection.
    本发明涉及具有式(I)异构体和立体异构体的杂环取代的新型4-取代-1,3-二氢-2H-苯并咪唑-2-酮衍生物,以及其药学上可接受的加合物盐和溶剂化物,其中R4、R5、Z和Het在权利要求中定义。本发明所述的化合物在呼吸道合胞病毒(RSV)的复制中具有抑制剂的作用。本发明还涉及制备这种新型化合物、包括这些化合物的组合物以及用于治疗呼吸道合胞病毒感染的化合物。
  • NOVEL 4-SUBSTITUTED 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH BENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS
    申请人:Janssen R&D Ireland
    公开号:US20150175608A1
    公开(公告)日:2015-06-25
    The present invention is concerned with novel 4-substituted 1,3-dihydro-2H-benzimidazol-2-one derivatives substituted with benzimidazoles having formula (I) tautomers and stereoisomeric forms thereof, and the pharmaceutically acceptable addition salts, and the solvates thereof, wherein R 4 , R 5 , Z and Het have the meaning defined in the claims. The compounds according to the present invention are useful as inhibitors on the replication of the respiratory syncytial virus (RSV). The invention further concerns the preparation of such novel compounds, compositions comprising these compounds, and the compounds for use in the treatment of respiratory syncytial virus infection.
    本发明涉及具有式(I)的苯并咪唑取代基的新型4-取代1,3-二氢-2H-苯并咪唑-2-酮衍生物的构象异构体和立体异构体形式,以及药学上可接受的加合物和其溶剂化物,其中R4、R5、Z和Het在权利要求中有定义。本发明的化合物可用作呼吸道合胞病毒(RSV)复制的抑制剂。本发明还涉及制备这种新型化合物、包含这些化合物的组合物以及用于治疗呼吸道合胞病毒感染的化合物。
查看更多